Theravance Biopharma Reports 6% Revenue Growth to $15.4 Million in Q1 2025

Theravance Biopharma, Inc. reported its financial results for the first quarter of 2025, revealing total revenues of $15.4 million, a 6% increase from $14.5 million in the same period last year. The revenue growth was primarily driven by the company's collaboration agreement with Viatris, which contributed $15.4 million in revenue, reflecting a rise in customer demand and increased doses pulled through the hospital channel. Despite the revenue increase, the company reported a net loss of $13.6 million, compared to a net loss of $11.7 million in the first quarter of 2024, resulting in a basic and diluted net loss per share of $0.27, up from $0.24 in the prior year.

Total expenses for the quarter were $29.8 million, up from $25.7 million in the previous year, with research and development (R&D) expenses increasing by 28% to $11.5 million, largely due to higher external-related costs associated with the ongoing Phase 3 clinical study of ampreloxetine. Selling, general, and administrative (SG&A) expenses also rose by 10% to $18.4 million, driven by costs related to strategic initiatives and pre-launch activities for ampreloxetine. The increase in expenses contributed to the wider net loss reported for the quarter.

In terms of operational developments, Theravance Biopharma's cash and cash equivalents increased significantly to $110.6 million as of March 31, 2025, compared to $37.8 million at the end of 2024. This increase was bolstered by a $50 million milestone payment received from Royalty Pharma related to the 2024 global net sales of TRELEGY. The company also reported a substantial improvement in cash flow from operations, generating $43 million in the first quarter, compared to a cash outflow of $1 million in the same period last year. The company’s total assets decreased slightly to $343.6 million from $354.2 million at the end of 2024.

Theravance Biopharma continues to focus on its strategic collaboration with Viatris for the commercialization of YUPELRI, which remains a key product in its portfolio. The company is also advancing its investigational drug ampreloxetine, which has received Orphan Drug Designation from the FDA for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy. Looking ahead, the company expects its cash resources to be sufficient to fund operations for at least the next twelve months, while it continues to navigate the complexities of clinical development and market conditions.